Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03277378 · ClinicalTrials.gov registry record · NA

Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial

A NA study of Chronic, Intractable Pain of the Trunk and/or Lower Limbs, sponsored by Abbott Medical Devices.

Completed
Registry status
NA
Development phase
270
Enrollment target
20
Study locations

NCT03277378: Completed NA study of Chronic, Intractable Pain of the Trunk and/or Lower Limbs, sponsored by Abbott Medical Devices.

NCT03277378 is a NA study of Chronic, Intractable Pain of the Trunk and/or Lower Limbs that has completed, run by Abbott Medical Devices. The registered enrollment target is 270 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03277378, a NA study of Chronic, Intractable Pain of the Trunk and/or Lower Limbs, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
NA
Development phase
270 participants
Enrollment target
20
Study locations

Study Summary

Prospective, multi-center, randomized, single blind study

Primary Outcome

The primary endpoint is the qualification rate for permanent system implant at the end of the initial trial evaluation period. Qualification for permanent system implant was defined by a composite where all the following conditions were met: * ≥ 50% patient reported pain relief (PRP) at the end of the trial evaluation * Trial evaluation period lasted for a minimum of 3 days * Physician recommends subject for permanent system implant * Subject reports a willingness to pursue a permanent system

Interventions

  • DEVICE lead placement followed by BurstDR stimulation

Study Locations (20)

Other

  • Frankston Pain Management - Frankston
  • North Shore Private Hospital - Saint Leonards
  • Hospital Elisabethinen GmbH - Graz
  • Wilhelminenspital Wien - Vienna
  • Sana Kliniken Duisburg Gm.bH - Duisburg
  • Medizinische Einrichtungen der Universität Düsseldorf - Düsseldorf
  • Hospital Gera -Zentrum für interdisziplinäre Schmerztherapie - Gera

Florida

  • Comprehensive Spine Institute - Clearwater
  • Florida Pain Institute - Merritt Island
  • National Pain Institute Winter Park - Winter Park

Nevada

  • Advanced Pain Care - Las Vegas
  • Nevada Advanced Pain Specialists - Reno

Oregon

  • Oregon Health & Science University - Portland
  • Spinal Diagnostics - Tualatin

California

  • Jason Edward Pope, MD - Santa Rosa

Illinois

  • Rush University - Chicago

Kansas

  • Kansas University Medical Center - Kansas City

Rhode Island

  • Rhode Island Hospital - Providence

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2017-09-22
Est. Completion 2018-10-12
Phase NA
Abbott Medical Devices

261 total trials

What the finished NCT03277378 record still lists

NCT03277378 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Chronic, Intractable Pain of the Trunk and/or Lower Limbs appearing as the primary indexed condition, and to 1 intervention - of which lead placement followed by BurstDR stimulation is the first listed.

NCT03277378 names 20 study sites across 10 states, led by Other, Florida, Nevada.

Frequently Asked Questions

What is clinical trial NCT03277378 about?

NCT03277378 is a clinical study titled "Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial". Prospective, multi-center, randomized, single blind study

What is the current status of trial NCT03277378?

This trial is currently completed. It is a NA study. The enrollment target is 270 participants. The study started on 2017-09-22. Estimated completion is 2018-10-12.

What conditions does trial NCT03277378 study?

This clinical trial studies the following conditions: Chronic, Intractable Pain of the Trunk and/or Lower Limbs.

What interventions are being tested in trial NCT03277378?

The interventions under investigation include: lead placement followed by BurstDR stimulation (DEVICE).

Who is sponsoring clinical trial NCT03277378?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03277378 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Kansas, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT03277378's enrollment target sits among peer trials

270 387th of 2000 higher than 1,609 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03277378, the US trial registry maintained by the National Library of Medicine. NCT03277378 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.